课题基金 / 基金详情

Genome Mining the Full Diversity of the Actinomycete Biosynthetic Universe for Neomorph Antibiotic Discovery

Genome Mining the Full Diversity of the Actinomycete Biosynthetic Universe for Neomorph Antibiotic Discovery
基因组挖掘放线菌生物合成宇宙的全部多样性,以发现 Neomorph 抗生素
批准号:
9253641
负责人:
Daniel Gray
金额:
$22.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-01-15 至 2017-10-14

项目摘要

项目成果

Daniel Gray的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 为了对抗多重耐药细菌感染,具有新作用机制的新型抗生素 都是非常需要的。寻找新的天然产物的基因组挖掘正在迅速取代传统方法 为了抗生素的发现。Warp Drive Bio已经对来自不同国家的135,000多株放线菌基因组进行了测序 来自世界各地,我们的专有基因组数据库包含大约3500,000个二级 代谢物基因簇。重要的是,在我们的数据库中确定的大约75%的聚类族尚未 在文献中有报道。我们广泛的基于微生物基因组学的方法是创新的,因为它提供了 发现具有新作用机制(MOA)的全新抗生素的前所未有的机会。 这个项目的重点将是识别、表达和测试编码新类的生物合成基因簇。 使用新型MOA来对抗当前和未来的耐药病原体,通过梳理我们广泛的 利用我们经过验证的基因组到药物平台,提供基因组资源和创新的生物信息学搜索 天然产物的发现。首先,我们将利用我们广泛的、互补的基因组资源来识别 克隆了10个候选新形态抗生素簇。我们把新奇的生物合成簇称为 我们已经构建了一条生物信息学分析管道,包括系统基因组和化学信息学 在基因和生物合成层面评估新颖性的工具。然后我们将利用我们的微生物基因组 通过搜索自耐药基因来预测哪些新形体簇具有抗生素活性的数据库 在新形态星团中。细菌利用各种自我抵抗机制来保护自己免受 它们正在积极地生产抗生素,这种特性可以利用基因组信息来开发。我们的 综合生物信息学分析,我们将提出10个候选新形态抗生素簇用于表达和 测试。将部署一个经过验证的合成生物学技术组合,用于重构生物合成 簇以增强未表达的簇的表达,或表达非常低的簇的表达 水平,以增加化合物的产量。最后我们开发了一种高通量发酵工艺, 生物分析和质谱学基础设施,以分析和识别新生物。因此,通过将一个 创新的基因组搜索新的生物合成簇嵌入抗性基因,与我们的整合 基因到化合物平台,我们将识别、设计和筛选候选新变形剂抗生素以解决 临床上对新型抗菌剂和新型MOA的需求日益增长。
英文摘要
ABSTRACT To combat multidrug-resistant bacterial infections, novel classes of antibiotics with new mechanisms of action are desperately required. Genome mining for novel natural products is quickly replacing traditional approaches to antibiotic discovery. Warp Drive Bio has sequenced over 135,000 actinomycete strain genomes from diverse sources worldwide, and our proprietary genomic database contains approximately ~3,500,000 secondary metabolite gene clusters. Importantly ~75% of cluster families identified in our database have yet to be reported in the literature. Our vast microbial genomics-based approach is innovative because it provides an unprecedented opportunity to discover entirely novel antibiotics with new mechanisms of action (MOAs). The focus of this project will be to identify, express, and test biosynthetic gene clusters encoding new classes of antibiotics with novel MOAs to combat current and future drug-resistant pathogens, by combing our vast genomics resources and innovative bioinformatics search with our validated genomes-to-drugs platform for natural products discovery. First, we will harness our extensive, complementary genomic resources to identify and clone 10 candidate neomorph antibiotic clusters. We term biosynthetic clusters that are novel as “neomorphs,” and we have constructed a bioinformatic analysis pipeline of phylogenomic and chemoinformatic tools to assess novelty at the genetic and biosynthetic levels. We then will utilize our microbial genomic database to predict which neomorph clusters possess antibiotic activity, by searching for self-resistance genes within the neomorph cluster. Bacteria utilize a variety of self-resistance mechanisms to protect against the antibiotics they are actively producing, and this property can be exploited using genomic information. Our integrated bioinformatic analysis we will advance 10 candidate neomorph antibiotic clusters for expression and testing. A validated portfolio of synthetic biology techniques will be deployed for refactoring biosynthetic clusters to enhance the expression of clusters that are not expressed, or which are expressed at very low levels, to increase compound production. Finally we have developed a high throughput fermentation process, bioassay, and mass spectrometric infrastructure to analyze and identify neomorphs. Thus, by combing an innovative genomic search of novel biosynthetic clusters with embedded resistance genes, with our integrated genes-to-compound platform, we will identify, engineer, and screen candidate neomorph antibiotics to address the growing clinical need for new antibacterial agents with novel MOAs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neurobiological basis of age-related deficits in attentional shifting and monitoring
  • 批准号:
    9257078
  • 项目类别:
  • 资助金额:
    $3.5万
  • 财政年份:
    2017
  • 负责人:
    Daniel Gray
  • 依托单位:
海外基金